Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers by Pfefferle, Adam D. et al.
RESEARCH ARTICLE
Genomic profiling of murine mammary tumors identifies potential
personalized drug targets for p53-deficient mammary cancers
Adam D. Pfefferle1,2, Yash N. Agrawal2, Daniel C. Koboldt3, Krishna L. Kanchi3, Jason I. Herschkowitz4,
Elaine R. Mardis3, Jeffrey M. Rosen5 and Charles M. Perou1,2,6,*
ABSTRACT
Targeted therapies against basal-like breast tumors, which are
typically ‘triple-negative breast cancers (TNBCs)’, remain an
important unmet clinical need. Somatic TP53 mutations are the
most common genetic event in basal-like breast tumors and TNBC.
To identify additional drivers and possible drug targets of this subtype,
a comparative study between human and murine tumors was
performed by utilizing a murine Trp53-null mammary transplant
tumor model. We show that two subsets of murine Trp53-null
mammary transplant tumors resemble aspects of the human basal-
like subtype. DNA-microarray, whole-genome and exome-based
sequencing approaches were used to interrogate the secondary
genetic aberrations of these tumors, which were then compared to
human basal-like tumors to identify conserved somatic genetic
features. DNA copy-number variation produced the largest number
of conserved candidate personalized drug targets. These candidates
were filtered using a DNA-RNA Pearson correlation cut-off and a
requirement that the gene was deemed essential in at least 5% of
human breast cancer cell lines from an RNA-mediated interference
screen database. Five potential personalized drug target genes,
which were spontaneously amplified loci in both murine and human
basal-like tumors, were identified: Cul4a, Lamp1, Met, Pnpla6 and
Tubgcp3. As a proof of concept, inhibition of Met using crizotinib
caused Met-amplified murine tumors to initially undergo complete
regression. This study identifies Met as a promising drug target in a
subset of murine Trp53-null tumors, thus identifying a potential
shared driver with a subset of human basal-like breast cancers. Our
results also highlight the importance of comparative genomic studies
for discovering personalized drug targets and for providing a
preclinical model for further investigations of key tumor signaling
pathways.
KEY WORDS: Basal-like breast cancer, Exome sequencing,
Genetically engineeredmousemodels, p53, Personalized genomics,
Whole-genome sequencing
INTRODUCTION
Human breast cancer is a heterogeneous disease that can be
segregated into at least six distinct subtypes based on gene
expression profiles: basal-like, claudin-low, human epidermal
growth factor receptor 2 (HER2)-enriched, luminal A, luminal B
and normal-like (Perou et al., 2000; Prat et al., 2010; Cancer
Genome Atlas Network, 2012). Although targeted therapeutics
exist for estrogen receptor (ER)-positive (Jordan, 2003) [luminal
A/B (Prat and Perou, 2011)] and HER2-positive (Hynes and Lane,
2005) [HER2-enriched (Prat and Perou, 2011)] tumors, targeted
treatments for triple-negative breast cancer (TNBC) [basal-like and
claudin-low (Prat and Perou, 2011)] remain an important unmet
clinical need (Carey et al., 2010). To address this, a research
emphasis has been placed on identifying the molecular drivers of
basal-like and claudin-low tumors that could be exploited as drug
targets for these subtypes.
Somatic TP53 mutations are one of the most frequent genetic
events in breast cancer, occurring in >80% of TNBCs (Cancer
Genome Atlas Network, 2012). Although there is a growing
appreciation for the consequences that TP53 gain-of-function
mutations impose on cell signaling (Brosh and Rotter, 2009;
Murphy et al., 2000), the majority of these TNBC TP53 mutations
are predicted to lead to loss of function (Bullock and Fersht, 2001).
This genetic foundation primes tumors to accumulate secondary
genetic aberrations by decreasing the cell’s ability to maintain
normal cell physiology (Murphy and Rosen, 2000; Hanel and Moll,
2012). Identifying the subset of genetic events that promote breast
cancer is important for informing tumor biology and for guiding
personalized treatment regimens. However, segregating genetic
drivers of tumorigenesis from passenger aberrations is inherently
difficult owing to the diversity of breast tumors and the large
number of candidate aberrations identified in genome-wide
profiling studies (Cancer Genome Atlas Network, 2012; Curtis
et al., 2012).
Comparative studies between human and murine tumors provide
an attractive approach for narrowing the genetic-driver candidate list
by highlighting conserved features between species (Pfefferle et al.,
2013; Silva et al., 2015). The murine Trp53-null mammary
transplant model (Jerry et al., 2000) is a particularly powerful
resource for identifying the genetic drivers of TNBC. From a
genetics perspective, the Trp53-null transplant model mimics the
loss of function seen in human tumors through the expression of a
truncated version of Trp53 (Jacks et al., 1994). In addition, tumors
from thismodel resemblemultiple human intrinsic subtypes of breast
cancer, including both basal-like and claudin-low (Herschkowitz
et al., 2012; Pfefferle et al., 2013). Identifying the genetic
mechanisms that explain this intra-model tumor heterogeneity
might help in determining the etiology of specific human subtypes.
From an experimental perspective, the transplantability of these
tumors allows for a single tumor to be expanded and exhaustivelyReceived 28 February 2016; Accepted 27 April 2016
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studied to verify that the conserved candidates are drivers of
tumorigenesis and/or to rigorously test therapeutics (Roberts et al.,
2012a,b; Usary et al., 2013; Bennett et al., 2012). For these reasons,
this study used the Trp53-null mammary transplant model to identify
genetic drivers, and thus potential drug targets, of basal-like breast
tumors.
RESULTS
Trp53-null transplant tumors are counterparts for multiple
expression subtypes of human breast cancer
The Trp53-null transplant model produces phenotypically and
genomically diverse tumors that can be classified into three major
subtypes/classes based on gene expression profiles: p53null-
BasalEx, Claudin-lowEx and p53null-LuminalEx (Pfefferle et al.,
2013). A crucial component of breast cancer comparative studies is
to properly identify corresponding human-to-murine subtype
counterparts. Once counterparts are determined, conserved
features can be identified to highlight the candidate genetic
drivers of those subtypes. For this purpose, a transcriptomic
comparison between the two species was performed. To do this,
we created gene signatures for each of our three previously identified
Trp53-null transplant classes using a two-class (class x versus all
others) Significance Analysis of Microarrays (SAM) analysis across
a 385-sample microarray dataset consisting of 27 murine models of
mammary carcinoma, and normal mammary tissue (Pfefferle et al.,
2013). Each signature was defined as all genes highly expressed in
the class of interest with a false discovery rate (FDR) of 0%. The
average of these signatures was calculated within each sample of the
UNC308 (Prat et al., 2010), Combined855 (Harrell et al., 2012) and
Metabric (Curtis et al., 2012) human breast cancer datasets to
identify which human tumors also highly expressed these same sets
of genes. As anticipated from previous human subtype associations
(Pfefferle et al., 2013), the murine p53null-BasalEx subtype
signature was highly expressed in basal-like human tumors and
the Claudin-lowEx signature was specific to the human claudin-low
subtype (Fig. 1A). Although the p53null-LuminalEx signature was
most highly expressed in basal-like human tumors, it was also highly
expressed in HER2-enriched and luminal-B tumors, indicating that
these murine tumors have expression features in common with
several human subtypes. Similar results were observed when we
compared 963 molecular-pathway-based signatures across the three
murine subtypes (Fig. S1) (Pfefferle et al., 2013).
One explanation for the transcriptomic associations observed in
Fig. 1A is that both the human and murine subtypes arise from
similar cell types within the mammary-gland hierarchy (Visvader,
2009). To address this possibility, a ‘differentiation score’ (D-Score)
was calculated for all tumors in the murine microarray dataset
(Fig. 1B) (Prat et al., 2010). Low scores indicate a tumor similarity
to adult mammary stem cells (aMaSCs), intermediate scores a
similarity to luminal progenitor (LumProg) cells, and high scores a
similarity to mature luminal (MatureLum) cells (Prat et al., 2010).
The D-Score varied across the three Trp53-null subtypes, with the
p53null-ClaudinlowEx subtype being the lowest, the p53null-
BasalEx being intermediate, and the p53null-LuminalEx being the
highest (P<0.05) (Fig. 1B); even though the p53null-LuminalEx
subtype had the highest D-Score among the three p53-null subtypes,
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Fig. 1. Human counterparts of Trp53-null
transplant tumors. (A) Genes highly
expressed within each Trp53-null transplant
class were identified using a two-class (class
x versus all others) SAM analysis (FDR 0%)
across our 385-sample murine microarray
dataset. The standardized average of these
gene signatures was calculated across more
than 3000 human tumors and displayed by
intrinsic subtype. (B) Tumor differentiation
scores (D-Scores) (Prat et al., 2010) were
calculated for all 385 murine samples and
displayed by intrinsic class. The D-Scores of
the three Trp53-null transplant classes were
compared using a Student’s t-test.
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its score was still relatively intermediate when compared across the
entire diverse murine tumor dataset. This indicates that, although the
p53null-LuminalEx class is the most ‘luminal’ of the three Trp53-
null classes, these tumors do not have as strong an association to
normal mammary gland MatureLum cells as do murine MMTV-
Neu tumors and human luminal A/B tumors (Pfefferle et al., 2015).
Taken together (Fig. 1 and Fig. S1), these results indicate that
p53null-BasalEx and p53null-ClaudinlowEx tumors are best
considered murine counterparts for human basal-like and claudin-
low subtypes, respectively. On the other hand, p53null-LuminalEx
tumors uniquely contained traits of multiple human intrinsic
subtypes, namely all three aggressive human subtypes (i.e. basal-
like, HER2-enriched and luminal B). This finding suggests that
p53null-LuminalEx tumors might be useful for studying aspects of
several human subtypes.
Profiling of secondary genetic aberrations highlights
conserved DNA copy-number changes between human and
murine Trp53-null tumors
In broad terms, disruption of normal Trp53 signaling leads to an
unstable genome due to a decreased ability to properly respond to the
presence of genetic aberrations (Bieging et al., 2014). This phenotype
leads to the accumulation of both small-scale mutations (e.g.
insertions, deletions) and large-scale chromosomal rearrangements
(e.g. translocations, copy-number variations) throughout the genome.
Specific genetic aberrations are predicted to be responsible for
determining a cell’s subtype fate during tumorigenesis, but
identifying these specific drivers has been challenging. Here, we
leveraged the power ofmultiple ‘omic’ technologies to interrogate the
secondary genetic aberrations underlying 43 different, independently
arisen Trp53-null transplant tumors (Table S1). Specifically, Illumina
sequencing and microarray technologies were used to produce four
datasets of varying sizes: DNA whole-genome sequencing (n=12),
DNA exome sequencing (n=25), DNA copy-number microarray
(n=43) and gene expression microarray (n=43) (Fig. 2). For the
purposes of our analyses, the DNA whole-genome and exome
sequencing datasets were combined into a single dataset by reducing
the whole genome samples to exome space, with all data deposited
into the Sequence Read Archive (SRA).
Given our hypothesis that the accumulation of specific secondary
genetic events during tumorigenesis drives the development of
specific tumor subtypes, we designed our statistical analyses to
identify those genetic events that were enriched within a specific
Trp53-null transplant classes as compared to the other two. Using
this approach with our combined DNA whole-genome and exome
dataset (Table S2), there were no identifiable genes that were
enriched with non-silent somatic mutations within the p53null-
BasalEx or p53null-LuminalEx classes, and only one gene in the
p53null-Claudin-lowEx class (Dchs2, P=0.005) when using a two-
class (class x versus all others) Fisher’s exact test (Fig. S2). We
therefore focused on large-scale chromosomal rearrangements,
amplifications and deletions as possible drivers of the murine
Trp53-null subtypes. An analysis of chromosome structural variants
(SVs) (Table S3) identified several rearrangements that were
enriched within each of the three Trp53-null transplant classes
using a two-class (class x versus all others) Fisher’s exact test
(Fig. 3). For instance, Mad2l1 was enriched for SVs in p53null-
BasalEx tumors. Mad2l1 plays an important role during metaphase
by preventing progression into anaphase until all chromosomes are
properly aligned (Schvartzman et al., 2010). Overexpression of
Mad2l1, as is the case in p53null-BasalEx tumors (FDR 0%), might
promote tumor development by further decreasing chromosome
stability (Sotillo et al., 2007). Although these SVs that are enriched
in certain Trp53-null transplant classes are intriguing, their
biological effect on the tumor phenotype is unknown at this time.
As a result, we were unable to definitively call any of these SVs
drivers of these classes.
The mechanism by which DNA copy-number variation leads to
changes in the tumor phenotype, however, is more intuitive and
more easily tested; therefore, we focused our attention on DNA
amplifications and deletions as secondary genetic drivers. We were
primarily interested in identifying genes in which the DNA copy-
number variation was highly correlated with their gene expression,
because this observation is consistent with causality. First, we
identified DNA copy-number changes that were statistically
enriched within each of our three Trp53-null transplant classes
using a two-class (class x versus all others) SAM analysis (Fig. 4).
Interestingly, both the p53null-BasalEx (Fig. 4A) and p53null-
LuminalEx (Fig. 4C) classes had distinct genomic regions of DNA
gains and losses, whereas the p53null-Claudin-lowEx (Fig. 4B) class
was relatively copy-number neutral, having no genomic regions
enriched with gains or losses; these results are consistent with
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Fig. 2. Murine Trp53-null tumor datasets. Sequencing and microarray technologies were used to produce four Trp53-null tumor datasets of varying sizes:
(i) whole genome sequencing (n=12), (ii) exome sequencing (n=25), (iii) DNA copy-number microarray (n=43) and (iv) gene expression microarray (n=43). The
intrinsic class of each sample is displayed on the dendrogram, with colored boxes being previously identified human subtype counterparts (Pfefferle et al., 2013).
The hierarchical clustering location of each p53-null tumor within the datasets is displayed as a vertical black strip. *The Trp53-null transplant model produces
heterogeneous tumors that primarily develop into one of these threemurine expression subtypes. For each dataset, the number of tumors studied from each of the
three murine classes highlighted by ‘*’ is displayed on the right-hand side of the figure.
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human studies that have highlighted several DNA copy-number
events specific to basal-like tumors but few, if any, events in
claudin-low tumors (Weigman et al., 2012). Specifically, p53null-
BasalEx tumors were defined by both gains and losses on
chromosome 8 and almost a complete loss of chromosome 12
(Fig. 4A), whereas p53null-LuminalEx tumors were defined by a
DNA amplification on chromosome 6 (Fig. 4C).
To narrow the list of potential genetic drivers within these
subtype-enriched regions, the Pearson correlation between DNA
copy number and gene expression was calculated to highlight the
genes that were the most concordant with DNA gains and losses
(Fig. 5). A Pearson correlation cut-off of 0.5 or greater was used to
define genes with a strong DNA-RNA association. A number of
interesting genes fell into this classification. As we previously noted
(Herschkowitz et al., 2012), Inpp4b (Pearson=0.5), a regulator of
PI3K-AKT signaling (Agoulnik et al., 2011), was lost in p53null-
BasalEx tumors on chromosome 12, similar to human basal-like
tumors (Weigman et al., 2012). Cul4a, which is located on the
p53null-BasalEx chromosome 8 amplicon, had a very high
correlation with its gene expression (Pearson=0.86). CUL4A is a
scaffolding protein for E3 ubiquitin ligase, which helps regulate the
cellular concentration of key protein substrates, including CHK1,
E2F1, ER-α and pol η, to name a few (Jackson and Xiong, 2009).
Given the wide variety of cellular phenotypes that these protein
substrates influence, such as proliferation and DNA repair (Jackson
and Xiong, 2009), CUL4A has been proposed as a possible cancer
driver and drug target (Sharma and Nag, 2014). The p53null-
LuminalEx tumors had a distinct amplification of chromosome 6
(Fig. 4) and, within this region, four genes had high correlation with
their gene expression levels (Fig. 5), includingMet (Pearson=0.92).
Met, which is also spontaneously amplified in a subset of Brca1/
Trp53 (Smolen et al., 2006) and lunatic fringe deleted (Xu et al.,
2012) mouse mammary tumors, is a receptor tyrosine kinase for
hepatocyte growth factor that regulates a variety of downstream
signal transduction pathways, including MAPK and PI3K-AKT
(Gastaldi et al., 2010).
Given that p53null-BasalEx tumors are counterparts for the
human basal-like subtype (Pfefferle et al., 2013) and that p53null-
LuminalEx tumors show features of all three aggressive human
subtypes (i.e. basal-like, HER2-enriched and luminal B), we
investigated The Cancer Genome Atlas (TCGA) DNA copy-
number dataset to determine whether these spontaneous murine
genetic events were also enriched in human basal-like breast tumors
to highlight conserved features across species (Cancer Genome
Atlas Network, 2012). Using a two-class (human basal-like versus
human non-basal) Fisher’s exact test, we identified 29 DNA copy-
number gains or losses commonly enriched in human basal-like
tumor genomes (P-value<0.05), which included gains of Met and
Cul4a and loss of Inpp4b (Fig. 5).
2250L (p53null-LuminalEx) tumors completely regress with
crizotinib treatment
Although the identification of conserved genetic events helps to
inform the molecular etiology of breast cancer, we were particularly
interested in identifying genetic drivers that were also drug targets.
Because conserved copy-number-amplified and overexpressed
genes might also serve as targets against human basal-like breast
tumors, we focused our attention on the genomic amplifications
because their protein products are more directly targetable than the
loss of protein function caused by deletions. Using this filtering
step, we were able to limit our candidate drug target list to 14 genes
for p53null-BasalEx tumors and four genes for p53null-LuminalEx
tumors (Fig. 6A). Because many of these genes are located on the
same amplified DNA segment, we hypothesize that specific genes
within these segments are responsible for driving tumorigenesis and
the others are passenger aberrations. To narrow the potential drug
target list further, we used genome-wide pooled short-hairpin RNA
(shRNA) dropout signature profiles obtained from the Donnelly –
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Fig. 3. Chromosome structural-
variation analysis. Displayed are
circos plots of the structural variants
(SVs) enriched within (A) p53null-
BasalEx, (B) p53null-Claudin-lowEx and
(C) p53null-LuminalEx tumors as
determined by a two-class (class x
versus all others) Fisher’s exact test.
The genes affected by these SVs are
listed under each circos plot.
752
RESEARCH ARTICLE Disease Models & Mechanisms (2016) 9, 749-757 doi:10.1242/dmm.025239
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
Princess Margaret Screening Centre (DPSC) Cancer Database
(Marcotte et al., 2012; Koh et al., 2012) for 29 human breast cancer
cell lines (Parker et al., 2009; Prat et al., 2013). This dataset was
constructed by targeting ∼16,000 genes with lentiviral shRNA
constructs to determine which genes are essential for cancer cell
survival and proliferation (Marcotte et al., 2012; Koh et al., 2012).
For our purposes, we used their in vitro breast cancer cell-line
experiments to validate our conserved drug candidates from Fig. 5.
Genes were considered essential if they were required for cell-line
survival and proliferation in greater than 5% of the cell lines as
defined by a Gene Activity Ranking Profile (GARP) P-value<0.05
(Marcotte et al., 2012; Koh et al., 2012). This relatively low cut-off
was designed to identify both personalized and universal tumor
drug targets. Using this final filtering step (Fig. 6A), wewere able to
highlight four potential essential genes for p53null-BasalEx tumors
(Cul4a, Lamp1, Pnpla6 and Tubgcp3) and one potential essential
gene for p53null-LuminalEx tumors (Met) (Fig. 6B).
The fact that Met was the only candidate remaining after our
filtering steps is particularly interesting given that genetically
engineered loss of Trp53 and overexpression of Met synergize to
induce murine mammary tumors (Knight et al., 2013). These
genetically engineered tumors were also responsive to crizotinib
(Knight et al., 2013), a US Food and Drug Administration (FDA)-
approved therapy for non-small-cell lung cancer (Solomon et al.,
2014) that inhibits Met and Alk (Shaw et al., 2011). Met DNA
amplification and expression had a bimodal correlation profile in
our dataset, with p53null-LuminalEx tumors preferentially having
this genetic aberration (Fig. 6C). Interestingly, a subset p53null-
Claudin-lowEx tumors were also Met-amplified, consistent with a
previous observation that Met synergizes with p53 loss to promote
tumors with claudin-low features (Knight et al., 2013). To formally
test whether Met was a personalized drug target in our Met-
amplified murine tumors, we treated three Trp53-null transplant
tumor lines with crizotinib. Whereas neither 2224L (p53null-
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Fig. 4. DNA copy-number analysis. Displayed in genomic order are the
median class DNA copy-number levels for (A) p53null-BasalEx, (B) p53null-
Claudin-lowEx and (C) p53null-LuminalEx tumors. DNA copy-number changes
enriched within each of the three Trp53-null transplant classes were identified
using a two-class (class x versus all others) SAM analysis. Genomic regions of
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BasalEx) nor T11 (p53null-Claudin-lowEx) tumors responded to
treatment (noting that both of these lines were not Met-amplified),
all of the 2250L (p53null-LuminalEx) tumors had complete
regression at the end of the 14-day treatment period (Fig. 6D).
Unfortunately, we were unable to test whether either of the Met-
amplified p53null-Claudin-lowEx tumors were sensitive to
crizotinib because they were not developed into transplantable
tumor lines at the time of initial sample collection. Given the
dynamic response of the 2250L (p53null-LuminalEx) tumors, we
hypothesize that the two Met-amplified p53null-Claudin-lowEx
tumors could have also been crizotinib-responsive. Because Alkwas
not differentially expressed across the three Trp53-null transplant
classes, we propose that this dynamic response is due to differences
in Met signaling, and, thus, spontaneous Met amplification is a
driver of tumorigenesis in this mouse model of human breast cancer.
DISCUSSION
Although increased public awareness and a greater understanding of
tumor biology have led to improved patient survival rates, breast
cancer is still the second leading cause of cancer related deaths in
American women and TNBC has the worst prognosis at present
(Cancer Genome Atlas Network, 2012; Curigliano and Goldhirsch,
2011). With so many patients either not responding or relapsing with
the current standard of care, the molecular mechanisms underlying
breast cancer are under intense investigation to identify new,
personalized drug targets (Curigliano and Goldhirsch, 2011;
Curigliano, 2012). This is especially true for TNBCs (basal-like
and claudin-low), for which targeted treatment options remain an
important unmet clinical need. Murine models provide an excellent
resource for identifying genetic drug targets by highlighting
conserved features between species (Pfefferle et al., 2013). Given
that somatic TP53 mutations are the most common genetic event in
human TNBC (Cancer Genome Atlas Network, 2012), the Trp53-
null mammary transplant mouse model is particularly useful for
studying the etiology of TNBCs because almost all tumors that arise
in this model are ER-negative, progesterone receptor (PR)-negative
and not HER2-amplified.
The Trp53-null transplant model produces heterogeneous tumors
that can be classified into three major subtypes/classes based on
gene expression profiles: p53null-BasalEx, Claudin-lowEx and
p53null-LuminalEx (Pfefferle et al., 2013); we do note that for
each transplant line, the subtype and genetics are consistent over
time and over multiple passages (Herschkowitz et al., 2012). Using
gene expression comparisons, we show that p53null-BasalEx tumors
are counterparts for the human basal-like subtype, whereas p53null-
Claudin-lowEx tumors are counterparts for the human claudin-low
subtype. Although p53null-LuminalEx tumors have features of
human luminal tumors (i.e. HER2-enriched and luminal B), these
tumors had intermediate ‘differentiation scores’ (D-Scores), similar
to luminal progenitor cells (Prat et al., 2010). The original
nomenclature for this class was derived by an observed
association to the human luminal subtypes based on a few
luminal markers (Herschkowitz et al., 2012), but more recent
work has shown that mature luminal and luminal progenitor cells
share many of the same features (Pfefferle et al., 2015; Kannan
et al., 2013). For instance, both mature luminal and luminal
progenitor cell fluorescence-activated cell sorting (FACS)
populations are EpCAM-positive (EpCAMpos) and Krt18pos (Lim
et al., 2009; Kannan et al., 2013), indicating that broader analyses
are required to distinguish between these cell types within tumors.
These findings help explain why p53null-LuminalEx tumors were
found to also have traits in common with the basal-like subtype,
because human basal-like tumors share features of luminal
progenitor cells (Pfefferle et al., 2015; Lim et al., 2009). These
observations indicate that p53null-LuminalEx tumors share features
with all three poor-outcome human subtypes (i.e. basal-like, HER2-
enriched and luminal B), including TP53 loss (Cancer Genome
Atlas Network, 2012).
Once these human-to-murine subtype counterparts were defined,
secondary-genetic-aberration profiling was performed to identify
candidate drivers of tumorigenesis. Through the use of a
comparative genomics analysis, we identified a number of murine
mammary subtype-specific copy-number events in our Trp53-null
transplant murine model, which mimicked similar events in human
C
0 1 2 3 4 5
0
1
2
3
4
log2 Met DNA Abundance
lo
g2
 M
et
 R
N
A
 E
xp
re
ss
io
n Pearson=0.92
T11
2224L
2250L
p53null-BasalEx p53null-ClaudinlowEx
p53null-LuminalEx
22
24
L 
Cr
iz
ot
in
ib
 (n
=5
)
22
24
L 
U
nt
re
at
ed
 (n
=5
)
D
−100
−10
0
10
100
1000
10000
22
50
L 
Cr
iz
ot
in
ib
 (n
=5
)
22
50
L 
U
nt
re
at
ed
 (n
=5
)
T1
1 
Cr
iz
ot
in
ib
 (n
=8
)
T1
1 
U
nt
re
at
ed
 (n
=8
)1
4 
D
ay
 P
er
ce
nt
 V
ol
um
e 
Ch
an
ge
A Candidate Drug Target Filtering Steps
p53null-BasalEx
p53null-LuminalEx
DNA Copy Number
Aberrations
(SAM FDR0%)
712 Candidates
67 Candidates
DNA Copy Number
Amplifications
(SAM FDR0%)
99 Candidates
52 Candidates
DNA-RNA
Correlation
(Pearson >0.5)
16 Candidates
4 Candidates
Human Basal-like
DNA Amplified
(FET p<0.05)
14 Candidates
4 Candidates
Human Breast Cancer 
Cell Line Essential
(GARP p<0.05)
4 Candidates
1 Candidate
B
p53null-BasalEx
Final Candidates
(% Cell Line Essential)
Cul4a (24.1%)
Lamp1 (6.9%)
Pnpla6 (17.2%)
Tubgcp3 (34.5%)
p53null-LuminalEx
Final Candidate
(% Cell Line Essential)
Met (6.9%)
Fig. 6. Candidate drug targets.
(A) Candidate-drug-target filtering
steps. (B) Final drug-target candidates
for p53null-BasalEx and p53null-
LuminalEx tumors. (C) Correlation of
DNA and RNA for Met. (D) Change in
tumor volume after 14 days of
continuous crizotinib treatment
displayed as box-and-whisker plots.
754
RESEARCH ARTICLE Disease Models & Mechanisms (2016) 9, 749-757 doi:10.1242/dmm.025239
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
basal-like tumors.Wewere particularly interested in genes that had a
high correlation between their copy number and gene expression
because, for these cases, we propose that the copy-number change is
the mechanism that directly influences the expression of the genes
within those genomic regions. We propose that a subset of these
conserved features might serve as effective drug targets against
human basal-like tumors. To highlight this subset of genes, we
utilized genome-wide pooled shRNA dropout signature profiles
obtained from the DPSC Cancer Database (Marcotte et al., 2012;
Koh et al., 2012) for 29 human breast cancer cell lines (Parker et al.,
2009; Prat et al., 2013). Through these various filtering steps, we
were able to identify four potential driver genes that were DNA-
amplified in p53null-BasalEx tumors. Although additional
experiments will be required to validate that these genes are
viable drug targets for this tumor subtype as they are for breast
cancer cell lines (Marcotte et al., 2012; Koh et al., 2012), we
propose that Cul4a is an attractive candidate because CUL4A
amplification and overexpression have been observed in the human
basal-like breast cancer subtype and were demonstrated to drive
tumorigenesis both in vitro and in vivo (Chen et al., 1998; Gupta
et al., 2002; Saucedo-Cuevas et al., 2014). By contrast,Met was the
only candidate driver gene of p53null-LuminalEx tumors. This class
had a reproducible DNA amplification of wild-typeMet, suggesting
that this could be a driver for this murine subtype. Crizotinib
treatment resulted in complete tumor regression at the end of the 14-
day treatment period in our 2250L (p53null-LuminalEx) tumor.
MET is an important receptor tyrosine kinase that can activate a
variety of signal transduction pathways, including MAPK and
PI3K-AKT. These results suggest thatMet is a driving oncogene in
this murine model subtype, and that crizotinib or similar MET-
targeted therapies might be effective against human basal-like
tumors that contain Met amplification. These experimental results
are particularly relevant given that about 20% of human basal-like
tumors have amplification ofMET. It is important to note, however,
that identifying effective single-agent therapies is inherently
difficult owing to the presence of resistant subpopulations within
the tumor and/or due to molecular mechanisms that allow the tumor
to evade treatment, such as kinome reprogramming (Duncan et al.,
2012). Although not directly tested here, we propose that crizotinib-
responsive tumors would eventually develop resistance and,
therefore, a drug combination would most likely be needed to
produce the best long-term outcome (Roberts et al., 2012b).
Although several clinical trials have been designed to test the
efficacy of anti-MET therapy in breast cancers (Ho-Yen et al., 2015),
early results suggest that they do not offer additional clinical benefit to
the current standard of care in patients with TNBC (Diéras et al.,
2015). We propose that these negative results were a reflection of the
overall clinical trial design in which TNBC patients were not
additionally stratified byMET-amplification status. This hypothesis is
supported by a non-small-cell lung cancer clinical trial, which found
that MET inhibition only added clinical benefit in the MET-positive
subpopulation of patients (Spigel et al., 2013). Similar companion
diagnostics should be considered to further stratify TNBC patients
into those with MET amplification/signaling to better identify those
patients most likely to respond to anti-MET therapy.
In conclusion, our work highlights the importance of comparative
genomic studies as a preclinical tool for discovering personalized
drug targets and for determining which patient populations are most
likely to respond to treatment. The identification of these drug
targets is especially important for TNBC, in which tumor
heterogeneity suggests that a universal drug target for this subtype
is unlikely. Given the wealth of mouse models and genomic data
available for breast cancers, we propose that these types of studies
should be an integral part of early phase drug development to
expedite the development of more personalized treatment regimens.
MATERIAL AND METHODS
Trp53-null transplant model
The BALB/c Trp53-null mouse model used in this study was created using a
germline mutation that produced a truncated and nonfunctional version of
Trp53 (Jacks et al., 1994). Trp53-null mice, however, are predisposed to
developing a variety of different tumor types, such as lymphomas, which
occur prior to breast tumor development (Jacks et al., 1994). To study p53
signaling in breast cancer, a transplant model was developed in which the
mammary pads of 8- to 10-week-old female Trp53-null mice were
transplanted into the cleared mammary pads of 21- to 24-day-old wild-
type BALB/c female recipient mice (Jerry et al., 2000). These mice were
then monitored until breast tumor development. A few of these samples
were frozen during tumor collection so that they could be used for
orthotopic, syngeneic transplant experiments following an initial
characterization of the primary tumor (Usary et al., 2013; Roberts et al.,
2012b). It is important to highlight that these individual tumor lines (e.g.
2224L, T11 and 2250L) differ from traditional cell lines in the fact that they
are never grown in vitro but are rather always grown in vivo through tumor
transplantations from one recipient mouse to another.
Gene expression
Microarray gene expression data from 27 murine models of mammary
carcinoma, and normal mammary tissue, were downloaded from the
following gene expression omnibus (GEO) entries: GSE3165, GSE8516,
GSE9343, GSE14457, GSE15263, GSE17916, GSE27101 and GSE42640
(Pfefferle et al., 2013). The 385-sample dataset was normalized to correct for
microarray platform bias as previously described (Pfefferle et al., 2013).
Tumor differentiation scores (D-Scores) were calculated across the
microarray dataset as previously described (Prat et al., 2010). Gene
expression signatures were created for the three murine classes enriched
with the Trp53-null transplant model (p53null-BasalEx, Claudin-lowEx
and p53null-LuminalEx) by performing a two-class (class x versus all
others) Significance Analysis of Microarrays (SAM) analysis on the
microarray dataset (Tusher et al., 2001). Signatures were defined as all
genes highly expressed in the class of interest with a false discovery rate
(FDR) of 0%. Similarly, pathway signatures were created as previously
described (Pfefferle et al., 2013). Expression scores for each gene and
pathway signature were determined by calculating the mean expression of
the signature within each sample in the UNC308 (Prat et al., 2010),
Combined855 (Harrell et al., 2012) and Metabric (Curtis et al., 2012)
human breast cancer datasets.
Whole-genome and exome sequencing
Illumina libraries were constructed with 1 mg of genomic DNA according to
the manufacturer’s protocol with the following modifications: (1) DNAwas
fragmented with a Covaris E220 DNA Sonicator to size range between
100 and 400 bp, (2) Illumina adaptor-ligated library fragments were
amplified in four 50-ml PCR reactions for 18 cycles, and (3) solid-phase
reversible immobilization bead cleanup was used for enzymatic purification
throughout the library process, as well as final library size selection targeting
300-500 bp fragments. For whole-genome sequencing, each library was
sequenced on four lanes of an Illumina HiSeq2000 instrument (2×101 bp)
per the manufacturer’s recommendations for an average of 65.7 Gb per
sample (∼19× haploid coverage). Reads were mapped to the Mm9 reference
sequence by BWA v.0.5.912 with the following parameters: -t 4 -q 5.
Alignments were merged and duplicates marked by Picard v.1.46. For
exome sequencing, individually barcoded libraries were pooled (three pools
of ten samples and one pool of five samples) prior to capture with the
Agilent mouse whole-exome kit. Following capture, pools were sequenced
on two lanes (one lane for the five-sample pool) of an Illumina HiSeq2000
instrument (2×101 bp). The DNA whole-genome and exome sequencing
datasets were combined into a single dataset by reducing the whole-genome
samples to exome space. All sequencing data was uploaded to the Sequence
Read Archive (SRA) under accession number SRP061710.
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Somatic mutation and SV detection
We performed comprehensive somatic mutation detection with the
whole-genome sequencing/exome data for each tumor sample using the
BALB/c data as a matched ‘normal’ control. Point mutations [single-
nucleotide variants (SNVs)] were called using SomaticSniper v0.7.3 and
VarScan v2.2.6, with the union of both callsets filtered to remove false
positives as previously described (Koboldt et al., 2012). SNVs that
overlapped mouse dbSNP 128 positions or that clustered at densities
greater than 2 per 500 kb were removed as likely germline variants.
Somatic indels were called using the Genome Analysis ToolKit (GATK-
1.0.5336). Somatic structural variants (SVs) were called using
BreakDancer v1.2 followed by de novo assembly with TIGRA.
Somatic SNVs, indels and SVs were annotated using an in-house
pipeline with transcripts from Ensembl 58 and NCBI build 37.
Analysis of somatic mutations and SVs
SNVs were collapsed to a gene level so that all non-silent somatic mutations
affecting the same gene were treated equally regardless of the actual
mutation. A two-class (class x versus all others) Fisher’s exact test was
performed to identify genes preferentially mutated within each Trp53-null
class (P-value<0.05). Somatic SVs were collapsed to a gene level so that all
SVs affecting the same genewere treated equally regardless of the actual SV.
Genes were defined as being affected by the SV if the start or end of the SV
occurred within the RefSeq gene region. A two-class (class x versus all
others) Fisher’s exact test was performed to identify genes preferentially
affected by SVs within each Trp53-null class (P-value<0.05). Because all of
the p53null-Claudin-lowEx tumors were analyzed using whole-genome
sequencing, a second two-class Fisher’s exact test was performed on these
tumors, in which only the 13 whole-genome profiled tumors were included
in the analysis to reduce the likelihood of the p53null-Claudin-lowEx-
enriched SVs being an artifact of methodology.
DNA copy number
DNA array comparative genomic hybridization (aCGH) data were
downloaded for the Trp53-null transplant tumors classified as p53null-
BasalEx, Claudin-lowEx or p53null-LuminalEx by gene expression profiling
from GEO entry GSE27101 (Herschkowitz et al., 2012). In addition,
genomic DNAwas extracted from five Trp53-null transplant tumors using a
DNeasy blood and tissue kit (Qiagen #69504), labeled with a Sure Tag
DNA kit (Agilent #5190-4240), and hybridized to 244K CGH microarrays
(Agilent #G4415A) as previously described (Herschkowitz et al., 2012).
DNA aCGH data was uploaded to GEO under accession number
GSE71071.
The 43-sample aCGH dataset was extracted from the University of North
Carolina (UNC) Microarray Database as log2 Cy5/Cy3 ratios, filtering for
probes with Lowess normalized intensity values greater than ten in the
control channel and for probes with data on greater than 70% of the
microarrays (Herschkowitz et al., 2012). The probes that passed these filters
were then oriented in genomic order and a ten-probe average was calculated
on consecutive groups of ten probes across each chromosome, resulting in a
final dataset of 23,181 features. A two-class (class x versus all others) SAM
analysis was performed to identify genomic regions of amplification or
deletion unique to each class (FDR of 0%).
Level-3 DNA segmentation data was downloaded from The Cancer
Genome Atlas (TCGA) data portal for 715 breast cancer samples (Cancer
Genome Atlas Network, 2012). Genomic regions of amplification and
deletion were defined as having a log2 segmentation value greater than
0.3 or less than −0.3, respectively. Genes preferentially amplified or deleted
in the human basal-like subtype were determined using a two-class (human
basal-like versus human non-basal) Fisher’s exact test (P-value<0.05).
Genes essential for the survival and proliferation of human
breast cancer cell lines
Genome-wide pooled shRNA dropout signature profiles were obtained from
the Donnelly – Princess Margaret Screening Centre (DPSC) Cancer
Database (Marcotte et al., 2012; Koh et al., 2012) for 29 human breast
cancer cell lines. Genes were considered essential if they were required for
cell-line survival and proliferation in at least 5% of cell lines as defined by a
Gene Activity Ranking Profile (GARP) P-value<0.05.
Crizotinib treatment
All mouse work was performed under protocols approved by the
UNC Institutional Animal Care and Use Committee. Of the 43 Trp53-null
transplant tumors used in this study, only four primary tumors
were available as tumor transplant lines for follow-up passaging
experiments: 2224L (p53null-BasalEx), 2225L (p53null-BasalEx), T11
(p53null-Claudin-lowEx) and 2250L (p53null-LuminalEx). A single
representative tumor from each Trp53-null transplant subtype was
randomly selected for crizotinib treatment experiments. One-million
tumor cells were suspended in Matrigel and injected subcutaneously into
the lower-right mammary pad of BALB/c wild-type female mice so that
each mouse developed a single tumor. When tumors were approximately
8 mm by 8 mm in size, mice were randomized to either the crizotinib
(ChemShuttle #877399-52-5) or untreated group. Crizotinib chow was
made byOpenSource Diets to a final concentration of 50 mg/kg/day andwas
given continuously over the 14-day treatment period to monitor tumor
growth. Tumor volumewas calculated from two-dimensional measurements
(Volume=[(width)2×length]/2). The percent change in volume at 14 days
was used to quantify response.
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